The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | SURPASS-ET: switching to ropeginterferon alfa-2b improves hematologic control in ET
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses updated findings from the Phase III SURPASS-ET study (NCT04285086) evaluating patients with essential thrombocythemia (ET) who switched from anagrelide to ropeginterferon alfa-2b. Dr Masarova highlights improvements in hematologic responses and blood count control following the switch, supporting the role of ropeginterferon alfa-2b as an important treatment option for patients requiring second-line therapy. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
